Nagasamudra Ashok, MD
Internal Medicine · San Jacinto, CANPI 1821036229
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 28.0% of the total. Reporting peaked in 2021 at $656 and has fallen 96.6% since, to $22 in 2025.
Across 82 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$497
- AbbVie$279
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$146
- Lilly USA, LLC$133
- Johnson & Johnson$125
- AstraZeneca$108
- plus $490 from 12 others
What the payments were for
- Food & beverage$1,778100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 33 | $497 |
| AbbVie(2 entities) | 16 | $279 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $146 |
| Lilly USA, LLC | 6 | $133 |
| Johnson & Johnson | 1 | $125 |
| AstraZeneca | 5 | $108 |
| Gilead | 3 | $82 |
| Amarin Pharma, Inc. | 3 | $67 |
| UCB, Inc. | 2 | $64 |
| Bayer | 2 | $54 |
| Abbott | 2 | $43 |
| Amgen | 2 | $42 |
| Shionogi Inc | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Pfizer | 1 | $25 |
| SK Life Science, Inc. | 1 | $25 |
| CMP Pharma, Inc. | 1 | $17 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,778 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 574 | $170,407 |
| AustedoDeutetrabenazine | 48 | $89,464 |
| SantylCollagenase Clostridium Hist. | 87 | $87,721 |
| OzempicSemaglutide | 76 | $78,208 |
| JanuviaSitagliptin Phosphate | 169 | $58,487 |
| NuplazidPimavanserin Tartrate | 21 | $52,197 |
| JardianceEmpagliflozin | 107 | $39,939 |
| XareltoRivaroxaban | 95 | $34,107 |
| Sevelamer Carbonate | 89 | $32,095 |
| Valganciclovir Hcl | 29 | $26,612 |
| Pantoprazole Sodium | 615 | $21,134 |
| NorliqvaAmlodipine Besylate | 20 | $20,230 |
| Diclofenac Sodium | 108 | $19,021 |
| MounjaroTirzepatide | 18 | $18,141 |
| Levetiracetam | 485 | $15,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $25 | $170,407574 claims |
| Johnson & JohnsonXarelto | $125 | $34,10795 claims |
| Lilly USA, LLCMounjaro, Trulicity | $133 | $32,27732 claims |
| CMP Pharma, Inc.Norliqva, Atorvaliq | $17 | $27,19947 claims |
| AbbVieCreon | $279 | $15,18027 claims |
| GSKBreo Ellipta, Incruse Ellipta | $12 | $15,10631 claims |
| AstraZenecaFarxiga | $108 | $7,06821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Jacinto
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.